Top Market Shifts Transforming the Empagliflozin, Dapagliflozin And Canagliflozin Market Landscape: Key Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Empagliflozin, Dapagliflozin And Canagliflozin Market Through 2025?
In recent times, the market size for empagliflozin, dapagliflozin, and canagliflozin has consistently expanded. Projected growth suggests an increase from $9.64 billion in 2024 to $9.94 billion in 2025, marking a compound annual growth rate (CAGR) of 3.1%. This growth during the historic period is likely due to several factors, including a global rise in type 2 diabetes cases, heightened awareness regarding the benefits of SGLT2 inhibitors, an increase in the senior population, the escalating prevalence of obesity, and a growing emphasis on personalized medicine.

What's the Projected Size of the Global Empagliflozin, Dapagliflozin And Canagliflozin Market by 2029?
We can anticipate consistent expansion in the market size of empagliflozin, dapagliflozin and canagliflozin over the upcoming years. By 2029, the market is predicted to reach an estimate of $11.06 billion with a Compound Annual Growth Rate (CAGR) of 2.7%. The projected expansion during this period is tied to a rising demand for oral medications for diabetes, increased funding in diabetes research and drug creation, escalating healthcare costs, increased recognition and diagnosis of conditions prior to diabetes, and emphasis on combination therapies. Key trends to watch in this forecast period include innovations in technology, combination therapies, telehealth services, health information analytics, and security of patient data.

View the full report here:
https://www.thebusinessresearchcompany.com/report/empagliflozin-dapagliflozin-and-canagliflozin-global-market-report

Top Growth Drivers in the Empagliflozin, Dapagliflozin And Canagliflozin Industry: What's Accelerating the Market?
The escalating number of diabetes cases worldwide is anticipated to boost the expansion of the market for empagliflozin, dapagliflozin, and canagliflozin. Diabetes, characterized by high blood sugar levels due to insufficient insulin production or poor insulin usage, remains a pressing health concern. The surge in diabetes cases can be linked to factors like inactive lifestyles, poor eating habits, inherited genetic traits, increasing urbanization, and an aging global population. These factors are worsened by limited healthcare accessibility and increasing global obesity rates. Treatments for diabetes, such as empagliflozin, dapagliflozin, and canagliflozin, help to decrease sugar levels in the bloodstream by blocking the sodium-glucose co-transporter-2 (SGLT2) in the kidneys, facilitating glucose excretion via urination. For example, the National Health Service (NHS) released data in June 2024 showing a dramatic increase in diabetes cases among individuals under 40, from 173,166 in 2022 to 216,440 in 2023. This significant increase underscores a worrying trend among this demographic, indicating a steep rise in the occurrence of diabetes. Consequently, this rise in diabetes prevalence is catalyzing the expansion of the empagliflozin, dapagliflozin, and canagliflozin market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18350&type=smp

What Trends Will Shape the Empagliflozin, Dapagliflozin And Canagliflozin Market Through 2029 and Beyond?
Key players in the markets for empagliflozin, dapagliflozin, and canagliflozin are concentrating their efforts on the creation of groundbreaking products such as treatments for pediatric type-2 diabetes. This approach aims to cater to a wider patient demographic and extend their influence in diabetes care. Managing pediatric type-2 diabetes involves maintaining blood sugar levels through lifestyle modifications, prescribed medication, and occasionally, tailor-made insulin therapy for children and teenagers. For instance, AstraZeneca, based in the UK, publicized in June 2024 that the US FDA endorsed its product Farxiga (dapagliflozin) to upgrade glycemic control in pediatric patients over ten years old with type 2 diabetes. This ratification followed the positive outcomes from the T2NOW Phase III clinical trial-one of the most comprehensive studies on pediatric type-2 diabetes-revealing that Farxiga considerably reduced HbA1c levels when compared to a placebo. The safety outline for Farxiga in this demographic paralleled those seen in adult patients with type-2 diabetes. This successful approval symbolizes a significant landmark as oral treatments for pediatric type-2 diabetes are scarce. Furthermore, it highlights AstraZeneca's commitment to providing ground-breaking treatments for cardiovascular, renal, and metabolic diseases.

What Are the Main Segments in the Empagliflozin, Dapagliflozin And Canagliflozin Market?
The empagliflozin, dapagliflozin and canagliflozin market covered in this report is segmented -

1) By Type: Empagliflozin, Dapagliflozin, Canagliflozin
2) By Application: Application I, Application II, Application III, Application IV
3) By Channel: Hospital, Pharmacy

Subsegments:
1) Empagliflozin: 10 Mg, 25 Mg, 50 Mg
2) Dapagliflozin: 5 Mg, 10 Mg
3) Canagliflozin: 100 Mg, 300 Mg

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18350&type=smp

Which Top Companies are Driving Growth in the Empagliflozin, Dapagliflozin And Canagliflozin Market?
Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., MSN Laboratories Private Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.

Which Regions Will Dominate the Empagliflozin, Dapagliflozin And Canagliflozin Market Through 2029?
North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2024. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18350

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.